JavaScript is Disabled
Your browser's JavaScript functionality is disabled. It has to be enabled to use this function of ConfTool.
Here you can find information on how to enable JavaScript
If you have any problems, please contact the organizers at laccei2026@conftool.pro.

Conference Agenda

Overview and details of the sessions of this conference. Please select a date or location to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).

Please note that all times are shown in the time zone of the conference. The current conference time is: 24th Aug 2026, 04:43:57am America, Santiago

Daily Overview

Session

22E: Biotechnology
Virtual location: VIRTUAL: Agora Meetings

Presentation 1

10:20am - 10:28am

Analysis of the cellular viability and migratory capacity of triple-negative breast cancer cells stimulated with doxorubicin used during neoadjuvant chemotherapy

María Fernanda Vallejos Paredes¹, Melissa Francesca Buitron Mercado¹, Jose Miguel Carpio-Carpio², Yuma Aracely Ita Balta², Angeline Caprice Riera Perez², José Antonio Villanueva-Salas¹, Celia Choquenaira-Quispe¹

1: Escuela Profesional de Farmacia y Bioquímica, Facultad de Ciencias Farmacéuticas, Bioquímicas y Biotecnológicas, Universidad Católica de Santa María, Arequipa, 04002, Peru; 2: Escuela Profesional de Ingeniería Biotecnológica, Facultad de Ciencias Farmacéuticas, Bioquímicas y Biotecnológicas, Universidad Católica de Santa María, Arequipa, 04002, Peru

Breast cancer remains a major public health problem, especially the triple-negative molecular subtype, due to its limited response to chemotherapy. Therefore, the objective of this study was to evaluate the cellular viability and migratory capacity of triple-negative breast cancer cells treated with doxorubicin, a drug used in neoadjuvant chemotherapy. For this purpose, the MDA-MB-231 cell line was used, cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% antibiotic. Response to treatment was evaluated using MTT, clonogenic, and wound healing assays. The results showed an IC₅₀ value of 0.3 µM for doxorubicin in the MDA-MB-231 cell line. It was also observed that, despite treatment, the cells retained partial migratory capacity. Taken together, these findings indicate that doxorubicin reduces cell viability but does not completely inhibit the migration of MDA-MB-231 cells, which could contribute to doxorubicin favoring the survival of this triple-negative molecular phenotype.